Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $6.00
Shares Offered
2,000,000
Deal Size
$10.00M
Company Description
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases.
Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances.
We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
Curanex Pharmaceuticals Inc
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jun Liu |
Contact Details
Address: 2 Jericho Plaza, Suite 101B Jericho, NY 11753 United States | |
| Phone | (718) 673-6078 |
| Website | curanexpharma.com |
Stock Details
| Ticker Symbol | CURX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0002025942 |
| Employer ID | 83-0741390 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jun Liu | Chief Executive Officer, President and Director |
| Dian Ying Jing | Director and Secretary |
| Haiyan Yang | Chief Financial Officer and Treasurer |
| Huijuan Zhong | Chief Science Officer |
| Liqin Xie | Chief Operating Officer |
| Ning Zhang | Chief Technology Officer |
| Yong Yan | Independent Director |
| Yanming Du | Independent Director |
| Xiaohui Hao | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 16, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |